In addition, siRNA efficiency was assessed as shown in Figure 4B. To determine the stage of viral entry in which DR5 plays a role, cells were treated with E64D (0.1 μM, a cysteine protease inhibitor) 1h before viral infection. This evidence concerns the gene TNFRSF10B and viral infectious disease.